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Objective: To evaluate the efficacy of blood glucose self-monitoring on glycemic control in
patients with non-insulin-treated type 2 diabetes by performing a meta-analysis.
Methods: Randomized controlled trials (RCTs) of the efficacy of blood glucose self-
monitoring were collected from the PubMed, EMBASE, Cochrane Library, CNKI, and VIP
databases. Data were analyzed by RevMan 5.1 software.
Results: Seven RCTs were included in this meta-analysis. The results indicated that blood
glucose self-monitoring significantly reduced the glycated hemoglobin (HbA1c) level by
0.41%. Subgroup analysis showed that while implementation of a diabetes management
regimen based on the blood glucose self-monitoring results effectively reduced the HbA1c
level by 0.42%, no significant improvement in HbA1c level control was observed with the
implementation of blood glucose self-monitoring alone.
Conclusion: Blood glucose self-monitoring combined with diabetes management effectively
improves glycemic control in patients with non-insulin-treated type 2 diabetes.
Copyright ª 2014, Chinese Nursing Association. Production and hosting by Elsevier
(Singapore) Pte Ltd. All rights reserved.1. Introduction
Diabetes has become a public health problem that seriously
influences patients’ quality of life. Determination of the(X.-H. Wang).
Nursing Association
sevier
g Association. Productionglycated hemoglobin (HbA1c) level is the gold standard
method of evaluating glycemic control in patients with dia-
betes [1]. Maintaining the HbA1c level at <7% can significantly
reduce the risk of diabetes complications [2] and improve the
prognosis. However, to achieve such a goal, patients withand hosting by Elsevier (Singapore) Pte Ltd. All rights reserved.
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blood glucose levels and follow a specific treatment regimen
to effectively control their fasting blood glucose and post-
prandial glucose levels. Self-monitoring of blood glucose
(SMBG) helps patients with insulin-treated diabetes to better
understand the role of their blood glucose levels in improving
glycemic control [3]. However, randomized controlled trials
(RCT) have shown that the efficacy of SMBG on glycemic
control in patients with non-insulin-treated type 2 diabetes
remains controversial. Poolsup et al. conducted a systematic
literature review of RCTs mainly published from 2000 to June
2009 [4]; however, no literature from Chinese databases was
included, and some new RCTs have been published since June
2009. Therefore, we performed a meta-analysis of RCTs pub-
lished since 2000 on the efficacy of SMBG on glycemic control
in patients with non-insulin-treated type 2 diabetes.2. Design and method
2.1. Study selection
RCTs were eligible for inclusion if they (1) compared the effi-
cacy of SMBG and non-SMBG on glycemic control in patients
with non-insulin-treated type 2 diabetes and (2) utilized
HbA1c (%) as the observation index. Studies that compared the
efficacy of SMBG with that of self-monitoring of urine glucose
were excluded.
2.2. Search strategies
The following electronic databases were accessed from
January 2000 to June 2012: PubMed, EMBASE, the Cochrane
Library, CNKI, and VIP. The keywords and strategies used in
the literature search were “(blood glucose self-monitoring OR
SMBG) AND (type 2 diabetes mellitus OR MODY OR NIDDM).”
Using a combination of keywords and free words, we pre-
viewed and manually retrieved potentially relevant studies
and evaluated the literature references when necessary.
2.3. Data extraction and analysis
Two analysts independently reviewed all studies to ensure
that each met the eligibility criteria. The following data were
extracted according to the prepared data extraction table: (1)
basic information regarding the study, (2) baseline data of the
participants, (3) methodological quality, (4) interventionTable 1 e Characteristics of studies included in the present me
Study Time Participants (n)
Intervention group Contro
Barnett et al. [7] (2008) 27 weeks 311 29
Davidson et al. [8] (2005) 6 months 43 4
Franciosi [9] (2011) 6 months 46 1
Guerci et al. [10] (2003) 6 months 345 34
Kleefstra [11] (2010) 12 months 22 1
O’Kane et al. [13] (2008) 12 months 96 8
Schwedes [12] (2002) 6 months 113 11characteristics, and (5) the outcome-measuring index.
Controversial outcomes were evaluated by a third party.
2.4. Quality assessment
This study applied the MaastrichteAmsterdam form devel-
oped from the Jadad scale and Delphi list to evaluate the
methodological quality of each study [5]. The form contains 19
items, 11 of which were used to evaluate the internal validity
according to the advice of Welschen et al. [6]: randomization,
allocation concealment, baseline comparability, blindness,
coordinated intervention comparability, adherence of partic-
ipants, loss to follow-up, outcome measures, and intention-
to-treat analysis. Items with “yes” results were accounted as
1 point, and studies with a score of 6þwere considered “good”
while those with a score of 6e were considered “poor.”
2.5. Data synthesis and statistical analysis
RevMan 5.1 software supplied by the Cochrane Collaboration
was used to conduct this meta-analysis. We used weighted
mean differences to count the changes in the HbA1c value. If
the value was unavailable, the following formula was used:
SD1ðCÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SD1ðBÞ2 þ SD1ðFÞ2  ð2 R1  SD1ðBÞ  SD1ðFÞÞ
q
,
where C represents the change in the value, B represents the
baseline value, F represents the final value, and R represents
the correlation coefficient. Previously reported correlation
coefficients range from 0.3 to 0.7 [7e12]; thus, we used a cor-
relation coefficient of 0.5 in the present study. The 95% con-
fidence interval (CI) was used to evaluate the effects. The
heterogeneity of the research results was assessed with the
chi-square test (Q test). When the results were statistically
homogeneous (P > 0.1, I2 < 50%), a fixed-effects model was
used; otherwise, a random-effects model was used. The
studieswere divided into two groups according towhether the
health care workers adjusted the diabetes management plan
based on the SMBG results: the “adjusted group” and “pure
SMBG group.” Subgroup analysis was then conducted.3. Results
3.1. Study selection
The initial search strategy yielded 611 articles. After screening
the titles and abstracts, 559 articles were excluded; after
reading the full text, a further 27 articles were excluded. Theta-analysis.
Baseline HbA1c (%, x  s) Quality score
l group Intervention group Control group
9 8.12  0.89 8.12  0.84 6
5 8.50  2.20 8.40  2.10 7
6 7.90  0.60 7.90  0.60 6
4 9.00  1.30 8.90  1.30 6
8 7.60  0.50 7.70  0.40 7
8 8.80  2.10 8.60  2.30 7
0 8.47  0.86 8.35  0.75 6
Study or Subgroup
Barnett 2008
Davidson 2005
Franciosi 2011
Guerci 2003
Kleefstra 2010
O'Kane 2008
Schwedes 2002
Total (95% CI)
Heterogeneity: Chi² = 10.41, df = 6 (P = 0.11); I² = 42%
Test for overall effect: Z = 10.07 (P < 0.00001)
Mean
-1.15
-0.8
-1.2
-0.88
-0.1
-1.9
-1
SD
1.14
1.6
0.1
1.54
0.9
1.84
1.08
Total
311
43
46
345
22
96
113
976
Mean
-0.91
-0.6
-0.7
-0.6
-0.1
-1.7
-0.54
SD
1.29
2.1
0.2
1.54
0.8
1.99
1.41
Total
299
45
16
344
18
88
110
920
Weight
16.8%
1.0%
60.2%
11.9%
2.3%
2.0%
5.8%
100.0%
IV, Fixed, 95% CI
-0.24 [-0.43, -0.05]
-0.20 [-0.98, 0.58]
-0.50 [-0.60, -0.40]
-0.28 [-0.51, -0.05]
0.00 [-0.53, 0.53]
-0.20 [-0.76, 0.36]
-0.46 [-0.79, -0.13]
-0.41 [-0.49, -0.33]
SMBG non-SMBG Mean Difference Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours SMBG Favours non-SMBG
Fig. 1 e Efficacy of SMBG on reduction of HbA1c (%).
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patients with diabetes (27 articles), (2) lack of the HbA1c
level as the outcome measure (12 articles), (3) comparison of
the efficacy of SMBG and that of the urine glucose level (2
articles), and (4) comparison of the efficacy of SMBG of
different strengths (4 articles). In total, seven studies were
included in the meta-analysis.
3.2. Study characteristics and methodological quality
All seven studies were RCTs with quality scores of >6 points,
indicating high methodological quality. The study character-
istics are shown in Table 1.
3.3. Synthesis of results
Seven studies showed efficacy of SMBG on glycemic control in
patients with non-insulin-treated type 2 diabetes [7e13] with
no significant heterogeneity among studies (I2¼ 42%, p¼ 0.11).
The study results showed that SMBG could reduce the HbA1c
level by 0.41% (95%CI, e0.49 to 0.33; p < 0.00001) (Fig. 1). The
fail-safe N (Nfs) was calculated by the following formula:
Nfs ¼ (SZ/1.64)2 e S, where S represents the number of studies
and Z represents the z value of the independent studies. The
Nfs was 74 in this meta-analysis; in other words, 74 articles
with negative outcomes would be required for the minimum
possibility of publication bias.
The studies were divided into two groups according to
whether the health care workers adjusted the diabetes man-
agement plan based on the SMBG results: the “adjustment
group” and the “pure SMBG group.” Subgroup analysis was
then conducted. The results of the meta-analysis showed that
the HbA1c level was 0.42% lower in the adjustment group thanStudy or Subgroup
Barnett 2008
Davidson 2005
Franciosi 2011
Guerci 2003
Schwedes 2002
Total (95% CI)
Heterogeneity: Chi² = 7.47, df = 4 (P = 0.11); I² = 46%
Test for overall effect: Z = 10.19 (P < 0.00001)
Mean
-1.15
-0.8
-1.2
-0.88
-1
SD
1.14
1.6
0.1
1.54
1.08
Total
311
43
46
345
113
858
Mean
-0.91
-0.6
-0.7
-0.6
-0.54
SD
1.29
2.1
0.2
1.54
1.41
Total
299
45
16
344
110
814
Wei
17.
1.
62.
12.
6.
100.
SMBG non-SMBG
Fig. 2 e Reduction of HbA1c (in the non-SMBG group (95% CI, e0.50 to 0.34, p < 0.00001)
(Fig. 2) [7e10,12] and that no obvious improvement in glycemic
control was seen in the pure SMBG group (mean difference,
e0.09; 95% CI, e0.48 to 0.29; p ¼ 0.63) [11,13] (Fig. 3).4. Discussion
4.1. SMBG can improve the effects of glycemic control
In the past, health care workers usually adjusted the diabetes
management plan according to the HbA1c level. In the 1970s,
the invention of the portable blood glucose meter allowed for
the performance of SMBG. Glycemic control was determined
to be more efficient when the frequency of blood glucose
monitoring was increased; blood glucose changes were
monitored at timely intervals; and exercise, diet, and medi-
cation were adjusted according to the results of fasting and
postprandial blood glucose levels rather than the HbA1c level
[14,15]. The results of SMBG can reflect the influence of various
life events on the blood glucose level, such as dining, sports,
mood reactions, and drugs, helping to detect hypoglycemic
events and assisting health care workers to establish indi-
vidualized lifestyle intervention plans and optimize drug
treatments. Thus, patients can better understand their blood
glucose levels and more effectively work together with the
medical staff in their disease management.
The efficacy of SMBG for glycemic control in patients un-
dergoing insulin therapy has been confirmed. Based on the
present meta-analysis, SMBG is also effective for glycemic
control in patients with non-insulin-treated type 2 diabetes,
decreasing the HbA1c level by 0.41%. A 1% decrease in the
HbA1c level in patients with type 2 diabetes means that theght
5%
1%
9%
4%
0%
0%
IV, Fixed, 95% CI
-0.24 [-0.43, -0.05]
-0.20 [-0.98, 0.58]
-0.50 [-0.60, -0.40]
-0.28 [-0.51, -0.05]
-0.46 [-0.79, -0.13]
-0.42 [-0.50, -0.34]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours SMBG Favours non-SMBG
%) in adjustment group.
Study or Subgroup
Kleefstra 2010
O'Kane 2008
Total (95% CI)
Heterogeneity: Chi² = 0.26, df = 1 (P = 0.61); I² = 0%
Test for overall effect: Z = 0.49 (P = 0.63)
Mean
-0.1
-1.9
SD
0.9
1.84
Total
22
96
118
Mean
-0.1
-1.7
SD
0.8
1.99
Total
18
88
106
Weight
52.6%
47.4%
100.0%
IV, Fixed, 95% CI
0.00 [-0.53, 0.53]
-0.20 [-0.76, 0.36]
-0.09 [-0.48, 0.29]
SMBG non-SMBG Mean Difference Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours SMBG Favours non-SMBG
Fig. 3 e Reduction of HbA1c (%) in pure SMBG group.
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25% and 11%, respectively, and that the risk of diabetic ne-
phropathy, retinopathy, and othermicrovascular diseaseswill
be reduced by 29% [16]. Therefore, SMBG can obviously
improve the prognosis of patients with diabetes.4.2. SMBG should be closely combined with diabetes
management
Five of the seven RCTs in thismeta-analysis guided patients to
adjust their diabetesmanagement plan according to the SMBG
results [7e10,12], and two educated patients on how to mea-
sure their blood glucose levels without guidance on how to
adjust their diabetesmanagement plan according to the SMBG
results [11,13]. The subgroup analysis results showed a 0.42%
decrease in the HbA1c level in the adjustment group and no
improvement in glycemic control in the pure SMBG group.
Thus, whether to combine the SMBG results with patient
management is an important factor influencing the efficacy of
SMBG on glycemic control [17]. Blind implementation of SMBG
without individualized management or health education will
not only increase medical expenses, but will also increase the
patients’ anxiety regarding to blood glucose control. Previous
studies have also found that the lack of reasonable interpre-
tation and application of the SMBG results prevents patients
with diabetes from reasonably responding to their SMBG re-
sults [18]. Therefore, SMBG should be a part of diabetes self-
management. Only when SMBG is effectively combined with
diabetes self-management education in a manner that
changes the patient’s lifestyle and treatment strategies will it
play its proper role.
4.3. Implications for further study
Amajor limitation of studies such as those evaluated herein is
the potential inaccuracy of measuring the effect of SMBG. The
most common factors affecting such inaccuracy are a failure
to regularly adjust the instruments and incorrect use of the
calibration solution [19]. Some studies included in this meta-
analysis did not evaluate the performance of instrument
adjustment or the operating skill of the patients, which is a
requirement for subsequent research [8,11]. The effect of
SMBG may be influenced by the baseline HbA1c level; thus,
future researchers should divide patients with non-insulin-
treated type 2 diabetes into several groups according to their
baseline HbA1c level when studying the effect of SMBG. RCTs
have been performed on the effect of SMBG on blood glucose
control [20,21], but no specific study on patients with non-insulin-treated type 2 diabetes has been performed in China
to date. This area urgently requires exploration.
4.4. Limitations
Publication bias was likely present because we only selected
published RCTs. An inadequate number of studies was
included for funnel plots analysis of possible bias. Although
every study obtained a MaastrichteAmsterdam score of 6,
the sample size of some studies [9,11] was too small to worsen
the research quality. Finally, we only analyzed the effect of
SMBG; the incidence of complications, the cost-effectiveness
ratios, and other related variables were not considered in
this meta-analysis; therefore, we could not comprehensively
evaluate the effect of SMBG.Conflicts of interest statement
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